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Introduction: Safety Pharmacology studieswere conducted inmouse, rat, and non-human primate to deter-
mine in vivo effects of antisense oligonucleotides (ASOs) on the central nervous system, respiratory system, and
cardiovascular system. Effects on the hERG potassium channel current was evaluated in vitro. Methods:
ASOs contained terminal 2′-O-methoxyethyl nucleotides, central deoxy nucleotides, and a phosphorothioate
backbone. Neurobehavior was evaluated by Functional Observatory Battery in rodents. Respiratory function
was directly measured in rodents by plethysmograph; respiratory rate and blood gases were measured in
monkey. Basic cardiovascular endpoints were measured in rat; cardiovascular evaluation in monkey involved
implanted telemetry units. In single and repeat dose studies ASOs were administered by subcutaneous injection
at up to 300 mg/kg, 250 mg/kg, and 40 mg/kg inmouse, rat, or monkey, respectively. Assays were performed in
HEK293 or CHO-K1 cells, stably transfectedwith hERG cDNA, at ASO concentrations of up to 300 μM.Results:No
apparent effects were noted for respiratory or CNS function. Continuousmonitoring of the cardiovascular system
inmonkey demonstrated no ASO-related changes in blood pressures, heart rate, or ECG and associated parame-
ters (i.e., QRS duration). Speciﬁc assessment of the hERG potassium channel indicated no potential for actions on
ventricular repolarization or modest effects only at excessive concentrations. Discussion: The absence of direct
actions on neurobehavior and respiratory function associatedwith the administration of ASOs in safety pharma-
cology core battery studies is consistent with published toxicology studies. The combination of in vitro hERG
studies and in vivo studies in rat and monkey are consistent with no direct actions by ASOs on cardiac cell func-
tion or electrical conduction at relevant concentrations and dose levels. Taken as a whole, dedicated studies fo-
cused on the safety pharmacology of speciﬁc organ systems do not appear to add signiﬁcant data for
interpretation of potential adverse effects. The need for dedicated studies for future ASOs in the same class is
questionable, as a more encompassing data set can be collected in repeat dose and longer-term toxicology
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Antisense oligonucleotides (ASOs) have demonstrated therapeutic
beneﬁt for the treatment of various cancers, and more recently this dy-
namic drug platform has been expanded to include chronic and non-
life-threatening conditions such as diabetes and cardiovascular disease.
A signiﬁcant advantage of this class of drugs is the direct targeting of a
speciﬁc mRNA through Watson–Crick base pairing, and subsequent
inhibition of disease-causing proteins. Therapeutic intervention is the
ultimate goal for the technology, and as such, treatment involves a
diversity of schedules, doses, and routes. This requires a thorough un-
derstanding of the molecular mechanisms, pharmacologic activity,
pharmacokinetic properties, toxicology and clinical efﬁcacy.
Pharmacology has been reported in animal models of disease
(Hassing et al., 2012; Lentz et al., 2013; Wheeler et al., 2012). Evidence
of antisense activity in patients has been demonstrated for several
targets in early clinical trials (Miner, Wedel, Xia, & Baker, 2006;
Monteleone et al., 2012; Stein et al., 2012), and in deﬁnitive trials for hy-
percholesterolemia (Gelsinger, Steinhagen-Thiessen, & Kassner, 2012;
McGowan et al., 2012; Ricotta & Frishman, 2012). General toxicology
has been reviewed (Farman & Kornbrust, 2003; Henry et al., 2012;
Jason, Koropatnick, & Berg, 2004; Levin, Henry, Monteith, & Templin,
2001); similarly, reviews on the therapeutic potential of ASOs have
been published (Bennett & Swayze, 2010; Malik & Roy, 2011).
Safety pharmacology is one area that has not been as well outlined
for ASOs. The conduct and objectives of safety pharmacology assess-
ment are described in ICH M3 (R2), ICH S7A, and ICH S7B. In general,
these guidance documents are focused on small molecules. Safety as-
sessment of large molecules, i.e., biotechnology-derived pharmaceuti-
cals, is outlined in ICH S6 (R1). Guidance for pharmaceuticals intended
for cancer indications, as described in ICH S9, may also be considered.
The manufacturing of ASOs is a chemical process, as is that for small
molecules; whereas the high degree of single-target speciﬁcity and
the potential for exaggerated pharmacology are more closely aligned
with large molecules, such as monoclonal antibodies (mAb).
AlthoughASOs are not speciﬁcally described in guidancedocuments,
the evaluation for potential undesirable functional effects of ASOs on
major physiological systems involve the same concepts and consider-
ations. Pharmacologic activity is a primary consideration in species
selection; evaluation and selection of an ASO for an endogenous
target almost exclusively includes activity in non-human primates. Sim-
ilar to that for biologics, the optimal candidate ASO for humans may or
may not have activity in rodents. Study design parameters, e.g., dose
ranges, routes of administration, and numbers of animals, are alsooften more similar to biologics, as compared to those for small
molecules.
In regard to safety pharmacology, the core battery of the central ner-
vous system, the cardiovascular system, and the respiratory system are
of highest interest. Additional systems such as renal/urinary, autonomic
nervous, gastrointestinal and others may be appropriate under certain
conditions. While the focus of these studies remains consistent across
drug classes, there are speciﬁc points for consideration in the evaluation
of anASO. The non-humanprimate has been a key toxicology species for
the development of ASOs, whereas safety pharmacology studies have
not been common in monkey, in particular neurobehavioral-based as-
sessments. Therefore, the evaluation of an ASOmay require both rodent
and non-rodent studies, and scientiﬁcally sound judgments on which
species, studies, and assays best fulﬁlling the objectives of the regulatory
guidelines for addressing safety pharmacology within a development
program.
The compilation of data described here is focused on the results of
six distinct ASOs with known targets and a scrambled ASO with no
known biologic target. Each was evaluated for effect in the core battery
systems of in vivo neurobehavior and respiratory and cardiovascular
function. The hERG assay is the most common in vitro means of
assessing the potential for repolarization abnormalities that can lead
to cardiovascular events, and although no inhibition was anticipated,
this analysis was included to provide a more robust analysis for safety
pharmacology.
It should be recognized that the ASOs described herein representing
biologic targets were intended for diverse clinical indications, and as
such the development programs for the ASOs each had a speciﬁc
focus. The objectives of each program are beyond the scope of this man-
uscript, but these do have an inﬂuence on the designs of the studies and
the data sets for consideration. Finally, studies were conducted within
different facilities and the speciﬁc details, e.g., endpoints measured in
a FOB and data analysis, were based on the facilities' standard operating
procedure(s), with prior reviewby the development team for assurance
for addressing any concerns and a robust scientiﬁc assessment.
As noted above, ASOs are not speciﬁcally called out in ICH guidance
documents, and therefore, the level of evaluation and approach for safe-
ty pharmacology is often on a case-by-case basis. The regulatory review
for ASOs also appears to involve case-by-case considerationswith scien-
tiﬁc rationale allowing for differences among programs. In light of this,
for certain ASOs discussed herein speciﬁc portions of safety pharmacol-
ogywere addressedwithin toxicology studies and the studies described
here cover only those studies dedicated to safety pharmacology. Fur-
thermore, it is not the authors' intent to make a strict head-to-head
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ation of an ASO as a pharmaceutical class and for determining the con-
text of speciﬁc sequences. A similar data set has not yet been published
for ASOs, and this and future publications are expected to increase the
knowledge base for these compounds.
2. Methods
2.1. Animal care and use
All procedures involving animals were approved and performed in
accordance with guidelines of the Institutional Animal Care and Use
Committee (IACUC) of the facility in which each study was conducted.
2.2. ASOs, doses, and time points used in the evaluation
The sequence,modiﬁcation pattern, targeted gene, and cross-species
activity for each of the ASOs is provided in Table 1. Each ASO can be de-
scribed as having 2′-O-methoxyethyl (2′MOE) nucleotides in the ﬁrst
ﬁve positions in both the 5′ and 3′ termini, deoxy nucleotides in the cen-
tral region, and a phosphorothioate backbone throughout the sequence.
ASOswere synthesized by Isis Pharmaceuticals, Inc. (Carlsbad, CA, USA)
and provided for each study as stock or as individual concentrations.
When required, dosing solutions were prepared as described for each
of the studies.
The dose ranges evaluated represent doses from toxicology studies
in mice (up to 300 mg/kg) rats (up to 250 mg/kg), or monkey (up to
40 mg/kg), and the highest doses aremultiples, ~10× to 30× for rodent
and ~3× to 10× for monkey, above potential clinical doses. Speciﬁc ob-
servations for clinical observations, serum chemistry and hematology,
and histopathology have been described (Farman & Kornbrust, 2003;
Henry et al., 2012; Jason et al., 2004; Levin et al., 2001), and these
doses are similar to those for which the hepatic, renal, immune stimula-
tion effects and complement activation (monkey only) occurwith ASOs.
Likewise, the concentrations for the hERG assay are similar to (25 to
50 μM) or greater than (N100 μM)peak concentrations achieved in tox-
icology studies, and greatly above the b5 μMconcentrations foundwith
common clinical doses.
The pharmacokinetics of an ASO are best described by rapid clear-
ance from the systemic circulation followed by uptake into tissues. Yu
et al. (2008) outlined the cross-species pharmacokinetics of an ASO in
mouse, rat, monkey, and human. Peak concentration (Cmax) occurs im-
mediately upon intravenous injection or at or near the end of an infu-
sion; following subcutaneous injection Cmax is approximately 30 min
post-dose. The elimination half-life (t1/2) in the systemic circulation is
~1 h or less across species. Elimination from the systemic circulation oc-
curs with a combination of nuclease-based metabolism, renal elimina-
tion, and uptake and deposition into tissues, primarily liver, kidney,
and other organs of the reticuloendothelial system. It is during the
period of systemic circulation of an ASO that is considered to be the
most likely for adverse effects upon the CNS and respiratory andTable 1
Sequence, chemical structure, target, and cross-species activity of the ASOs.
ASO ID
no.
Sequencea Target Cross-species activity
116847 CTGCTAGCCTCTGGATTTGA PTEN Human/monkey/rat/mouse
141923 CCTTCCCTGAAGGTTCCTCC Scramble ASO No perfect matches in
any species
345198 GTCAAAGGTGCTTTGGTCTG GCCR Human/monkey/rat/mouse
353512 TCCCATTTCAGGAGACCTGG CRP Human/monkey
379804 CCATCCTGGTACATTCCCAC ApoB Mouse/rat
420476 TTCATGTGTCTGCATCATGT GCCR Human/monkey
487660 CCAGCTCAACCCTTCTTTAA α1-Antitrypsin Human/monkey
a Bold face type represents 2′-O-methoxyethyl nucleotides, italicized type represents
DNA nucleotides.cardiovascular systems. Therefore, data collection and monitoring
were focused on early time periods following dosing.
2.3. Evaluation on neurobehavior in mice
ISIS 420476was dissolved in phosphate buffered saline (PBS) at 5, 10,
or 25 mg/mL to achieve dose levels of 50, 100, or 250 mg/kg, respective-
ly, and administered as a single subcutaneous dose. Controls were ad-
ministered PBS at the same dose volume of 10 mL/kg. Eight Crl:
CD1(ICR) male mice (Charles River UK Limited), 6 to 7 weeks of age
and body weight range 27.8 to 37.4 g at study initiation, were assigned
to each group. Neurobehavioral observations were recorded pre-dose
(0 min) and at 30, 90, 150 and 300 minpost-dose. The speciﬁc endpoints
for evaluationwere: death, restlessness, apathy,writhing,ﬁghting, stereo
typed behavior (described type), tremor, twitches, convulsions, exoph-
thalmos, respiration, alertness, startle response, loss of righting reﬂex,
abnormal body carriage (described type), abnormal gait (described
type), straub tail, piloerection, pupil diameter, touch response, fearful-
ness, pinna reﬂex, corneal reﬂex, catalepsy, passivity, aggressiveness,
body tone, grip strength, cutaneous blood ﬂow, cyanosis, ptosis, lacrima-
tion, salivation, pain response, paralysis, grooming, diarrhea, vocaliza-
tion, and increased urination.
ISIS 487660was given subcutaneously at 40, 100, or 300 mg/kg, as a
single dose, using a dose volume of 10 mL/kg and concentrations of 4,
10, or 30 mg/mL in PBS. Controls received PBS only. Ten males and 10
females were assigned to each of the dose or control groups. Observa-
tion for neurobehavioral changes were recorded pre-dose and at 60,
120, and 360 min and 24 h post-dose. Animals were evaluated for loco-
motor activity, tail elevation, tremors, convulsion, abdominal tone, cat-
alepsy, traction, righting reﬂex, pinna reﬂex, piloerection, skin
coloration, respiration rate (observed), palpebra size (eyelid), exoph-
thalmos, lacrimation, salivation, diarrhea, startle reﬂex, and death.
Data collected in the mouse was analyzed for statistical signiﬁcance
using StarTox version 3.2.1 (Graham Laboratories, New Braunfels, TX,
USA). Analysis of variance (ANOVA) was used to test for group differ-
ences. When the results were statistically signiﬁcant (p b 0.05) inter-
group comparisons were made using Student's t-tests, with the error
mean square from one-way ANOVA. Body temperature and spontane-
ous locomotor activity results were compared to controls using
ANOVA followed by Williams' test.
2.4. Evaluation on neurobehavior in rats
2.4.1. Single dose
ISIS 353512 was dissolved in PBS at 20, 40, or 100 mg/mL to achieve
dose levels of 50, 100, or 250 mg/kg, respectively. Controlswere admin-
istered PBS at the same dose volume, 2.5 mL/kg, and dose route, subcu-
taneous injection. Tenmale and 10 female Sprague–Dawley rats (Orient
Bio Co., Ltd., Kyunggi-do, Korea) were assigned to each group. At the
time of dosing, rats were approximately 5 weeks of age with body
weights ranging from 130 to 159 g and 123 to 145 g for males and fe-
males, respectively. Neurobehavior of the animals were observed and
recorded pre-dose and at 30, 90, 180, and 360 min and 24 h post-dose.
2.4.2. Repeat dose
ASOs were dissolved in PBS at a concentration of 50 mg/mL. ISIS
116847 or ISIS 379804 was administered at 50, 100 or 150 mg/kg
(1, 2, and 3 mL/kg, respectively). ISIS 345198 or ISIS 141923was admin-
istered at 150 mg/kg (3 mL/kg). Controls were administered PBS
(3 mL/kg) only. Each group was composed of four male (132–147 g)
and four female (113–132 g) Sprague–Dawley rats (Orient Bio Co.,
Ltd., Kyunggi-do, Korea) approximately 6 weeks of age at study initia-
tion. Doses were administered by subcutaneous injection on Days 1, 4
and 8. On Day 8, observations were recorded pre-dose and at 45, 90,
180, and 360 min post-dose.
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Neurobehavior was evaluated by observation of signs during visual
inspection or elicited by speciﬁed handling of the animals. Animals
were observed for the presence of locomotor activity, tail elevation,
tremors, convulsion, abdominal tone, catalepsy, righting reﬂex, grip
strength (traction), pinna reﬂex, piloerection, skin color, respiration
rate, palpebra size (eyelid), exophthalmos, lacrimation, salivation, diar-
rhea, startle reﬂex, and death. Body temperature was also measured at
each time point.
Statistical analysis was performed using the GraphPad Instat pro-
gram (GraphPad Software, Inc., LA Jolla CA, USA). Variance of numerical
datawas checked by the Bartlett test; if the variancewas homogeneous,
the datawas subjected to ANOVA; otherwise, theywere analyzed by the
Kruskal–Wallis H test. Dunnett's multiple comparison tests were con-
ducted and data were considered to be signiﬁcant at p b 0.05.
2.5. Evaluation of respiration in conscious mice
Eight Crl:CD1(ICR)malemice/group (Charles River UK Limited), 6 to
7 weeks of age and 29.6 to 38.0 g at study initiation, were given a single
subcutaneous dose of ISIS 420476 at 50, 100 or 250 mg/kg (6, 12 and
30 mg/mL in PSB, respectively; 8.33 mL/kg). Baclofen (Sigma-Aldrich
Co., St. Louis MO, USA) was dosed at 20 mg/kg as a study positive
control.
Prior to dose administration, respiration rate, tidal volume, and
minute volume were measured for a 60 minute period in unrestrained
animals in a whole body plethysmograph (Buxco Research Systems,
Wilmington NC, USA). Pre-dose data was taken as the mean value of
the last 30 min of data collection. Post-dose time points were 30, 60,
90, 120, 150, 180, 210 and 240 min and 24 h. Data were the mean of
ten 2 minute intervals around each time point, with the exception of
the 240 minute and 24 hour time points which were the mean of the
last 20 min of data collection for each.
Analysis of covariance (ANCOVA) was carried out on the data for
each post-dose time point with pre-dose data included as a covariate
in the analyses. Following the ANCOVA, control (PBS) was compared
to the ASO-treated groups using Williams' test. Comparisons were
made between the PBS group and the positive control (baclofen)
group using Student's t-test based on the error mean square from the
ANCOVA. A signiﬁcance level of p b 0.05 was used for all evaluations.
2.6. Evaluation of respiration in conscious rats
2.6.1. Single dose
Four groups of eight male Sprague–Dawley rats/group (Orient Bio
Co., Ltd., Kyunggi-do, Korea) were used for evaluation of respiration
rate, tidal volume, and minute volume. At study initiation rats were ap-
proximately 6 weeks of age and ranged in weight from 112 to 128 g.
ISIS 353512 was evaluated following a single subcutaneous dose of 0
(control), 50, 100, or 250 mg/kg (2.5 mL/kg; 20, 40, and 100 mg/mL
in PBS, respectively).
2.6.2. Repeat dose
On Days 1, 4 and 8, ISIS 116847 or ISIS 379804 was administered
subcutaneously at an ASO dose of 50, 100 or 150 mg/kg (1, 2, and
3 mL/kg, respectively; 50 mg/mL in PBS); ISIS 345198 or ISIS 141923
was administered at 150 mg/kg (3 mL/kg; 50 mg/mL in PBS). Controls
were administered PBS (3 mL/kg) only. Male Sprague–Dawley rats
(Orient Bio Co., Ltd., Kyunggi-do, Korea) were used for the study and
were approximately 6 weeks of age and body weights ranged from
171 to 184 g at study initiation. Eight animals were assigned to each
of the ASO-treated or control groups.
2.6.3. Measurement and statistical analysis
Before initiation of dosing on Day 1 (ISIS 353512) or Day 8 (other
ASOs), baseline data for respiration rate, tidal volume and minutevolume was obtained for a 10 minute period in unrestrained animals
in a whole body plethysmograph (Buxco Research Systems, Wilming-
ton, NC USA). Pulmonary function was then measured for a 10 minute
period at 45, 90, 180, and 360 min post-dose. Statistical analysis was
performed using the GraphPad Instat program (GraphPad Software,
Inc., La Jolla CA, USA). Variance of numerical data was checked by the
Bartlett test; if the variance was homogeneous, the data was subjected
to ANOVA; otherwise, they were analyzed by the Kruskal–Wallis H
test. Dunnett's multiple comparison tests were conducted and data
were considered to be signiﬁcant at p b 0.05.
2.7. Evaluation of the cardiovascular system in rats
Each group was composed of ﬁve male rats (Orient Bio Co., Ltd.,
Kyunggi-do, Korea). Controls were dosed subcutaneously with PBS
(3 mL/kg) only. On Days 1, 4, and 8, groups assigned to receive ISIS
116847 or ISIS 379804 were dosed subcutaneously with 50, 100 or
150 mg/kg (1, 2, and 3 mL/kg, respectively); ISIS 345198 and ISIS
141923 were administered at 150 mg/kg (3 mL/kg). On Day 7, all ani-
mals were anesthetized with 50 mg/kg pentobarbital sodium and a
polyethylene cannula was surgically inserted into the femoral artery.
Prior to dosing onDay 8, baselinedatawas collected in freelymoving
conscious animals via the arterial catheter connected to a blood pres-
sure (BP) transducer (BIOPAC System Inc., Goleta CA, USA), and mean
BP and heart rate were recorded for a 10 minute period using a BP re-
cording system (BIOPAC System Inc., Goleta CA, USA). Post-dose data
were collected at 45, 90, 180, and 360 min. Statistical analysis was per-
formed using the GraphPad Instat program (GraphPad Software, Inc., La
Jolla, CA, USA). Variance of numerical data was checked by the Bartlett
test; if the variance was homogeneous, the data was subjected to
ANOVA; otherwise, they were analyzed by the Kruskal–Wallis H test.
Dunnett's multiple comparison tests were conducted and data were
considered to be signiﬁcant at p b 0.05.
2.8. Evaluation on cardiovascular system in unrestrained
non-human primates
An ascending dose study was used for the evaluation of ISIS 487660.
There was a minimumwashout period of 3 days between the dosing of
the control (PBS; 0 mg/kg) and low (12 mg/kg) dose, and a 1 week
washout between the dosing of the low and high dose (40 mg/kg)
groups. All doses were given by subcutaneous injection.
Four male cynomolgus monkeys of Cambodian origin (SNBL USA,
Alice TX, USA) were surgically implanted with telemetry transducers
(Data Sciences International, St. PaulMN, USA) for continuous collection
of hemodynamic, body temperature, and ECG data; and with arterial
vascular access ports (Access Technologies, Skokie IL 60076, USA) for
collection of arterial blood. Collection of cardiovascular data began at
least 2 h before each dose, and ended after the last time point. Data
was speciﬁcally analyzed at−60 min (prior to dose) and 60, 120, 180,
240, 300, 360, and 720 min and 24 h post-dose. Measurement of systol-
ic, diastolic, and mean arterial pressure, heart rate, respiratory rate,
body temperature, and lead II ECG parameters (PR interval, QRS dura-
tion, RR interval, and QT interval) were acquired from each animal at
each time point. Following established procedures for the laboratory,
the lead II QT interval was corrected for variations in heart rate using
Fridericia QTc interval (QTcF) and an individual animal correction factor
(QTcI). Representative ECG tracings were evaluated for disturbances in
rhythm and waveform morphology TcI prior to dosing, at the 240
minute post-dose time point, and at the end of the evaluation period.
Blood sampleswere collected at 240 min post-dose for ISIS 487660 con-
centration analysis. Arterial blood sampleswere taken prior to dose and
at 360 min post-dose for PO2, PCO2, pH, and SO2% assessments.
Statistical analysis was performed using GraphPad Prism Version
4.03 (GraphPad Software, Inc., La Jolla CA, USA). Comparisons were
made between the control and ASO-treated groups using Friedman
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blood gases which were compared using one-way ANOVA. Differences
between the control and ASO treatment groups were considered to be
statistically signiﬁcant at p b 0.05.
Eight female cynomolgusmonkeys of Chinese origin (approximately
3–5 years of age, weight range 2.7–3.3 kg; Covance Research Products,
Inc.) were surgically implanted with telemetry units (Data Sciences
International, St. Paul MN, USA) for evaluation of ISIS 420476. All eight
animals received the vehicle control (subcutaneous injection of PBS)
on Day 1; on Day 4, four animals each received a subcutaneous dose
of 12 or 40 mg/kg (0.4 mL/kg dose volume). Systolic, diastolic, and
mean arterial blood pressures, heart rate (derived from blood pressure
and ECG), and ECG were monitored continuously from at least 2 h
prior to dosing until at least 24 h post-dose. ECG parameters included
RR interval, PR interval, QRS duration, QT interval, and corrected QT
(QTc) interval. For this study and data collectionmethods the QTc inter-
val was calculated as described by Spence, Soper, Hoe, and Coleman
(1998) and modiﬁed by Miyazaki and Tagawa (2002). Representative
ECG tracings were printed at approximately 1 h prior to dosing, at ap-
proximately 3.5 h post-dose, and within the last hour of the data re-
cording sessions, for visual evaluation.
A Repeated Measures Analysis of Covariance (rANCOVA) was per-
formed for each endpoint, with post-treatment group mean results
(Day 4) compared to the group mean results collected on Day 1 (PBS
treatment) from the matching animals. Akaike's Information Criterion
(AIC) was utilized for model selection. This approach takes into account
statistical goodness of ﬁt and the number of parameters that have to be
estimated to achieve a particular degree of ﬁt. The AIC penalizes for the
addition of parameters, and thus selects a model that ﬁts well but has a
minimum number of parameters. Lower values indicate the preferred
model, and results from the smallest AIC were used. The ﬁrst order
Kenward–Roger (KR) degrees of freedom approximation was utilized.
When the ‘treatment by time’ interaction was signiﬁcant (p b 0.05),
each treatment group Least Squares mean (LSmean) was compared to
the control group LSmean using a 2-sided Student's t-test; if this was
not signiﬁcant (p ≥ 0.05), the treatment main effect was evaluated. If
the treatment main effect was signiﬁcant a 2-sided Student's t-test
was used to compare treated to control, using the overall segment
LSmeans; if not signiﬁcant no further analysis was conducted. For respi-
ratory rate no additional analysis was performed following the
rANCOVA.
2.9. Evaluation on hERG channel current
2.9.1. Cell culture and expression of hERG in HEK293 cells
HEK293 cells were stably transfected with hERG cDNA, the lineage,
procedures, and historical data for which was established within the fa-
cility which testing occurred. Stable transfectants were selected by
coexpression with the G418 resistance gene incorporated into the
expression plasmid. Cells were cultured in Dulbecco's Modiﬁed Eagle
Medium/Nutrient Mixture F-12 (D-MEM/F-12) supplemented with 10%
fetal bovine serum, 100 U/mL penicillin G sodium, and 100 μg/mL strep-
tomycin sulfate. Selection pressure was maintained with 500 μg/mL
G418 in the culture medium. All reagents were obtained from Sigma-
Aldrich (St. Louis Mo, USA).
2.9.2. Electrophysiological recordings in HEK293 cells
Cells were transferred to the recording chamber and superfused
with HEPES-buffered physiological saline (HB-PS; 137 mM NaCl;
4.0 mM KCl; 1.8 mM CaCl2; 1 mM MgCl2; 10 mM HEPES; 10 mM glu-
cose; pH adjusted to 7.4 with NaOH). The Micropipette Solution for
whole cell patch clamp recordingswas composed of 130 mMpotassium
aspartate; 5 mM MgCl2; 5 mM EGTA; 4 mM ATP; 10 mM HEPES; pH
adjusted to 7.2 with KOH. All reagents were obtained from Sigma-
Aldrich (St. Louis MO, USA).Assays were performed at 33 to 35 °C. A patch-clamp ampliﬁer was
used for whole cell recordings. Cells were held at −80 mV prior to
study start. Onset and steady state inhibition of hERG potassium current
weremeasured using a pulse pattern with ﬁxed amplitudes (condition-
ing prepulse +20 mV for 1 s; repolarizing test ramp to −80 mV
(−0.5 V/s) repeated at 5 s intervals). Each recording ended with a
ﬁnal application of a supramaximal concentration of E-4031 (0.5 μM
supplemented with 0.3% DMSO) to assess the contribution of endoge-
nous currents. The remaining uninhibited currentwas subtracted to de-
termine the potency for hERG inhibition. ISIS 487660 was tested at 108
and 324 μM. For ISIS 420476, the concentration range was 25, 50, 100
and 150 μM. Steady state was deﬁned by the limiting constant rate of
change with time (linear time dependence). The steady state before
and after ASO application was used to calculate the percentage of cur-
rent inhibited at each concentration.
Data acquisition and analyses were performed using the suite of
pCLAMP programs (Ver. 8.2; Molecular Devices, LLC, Sunnyvale CA,
USA). Percent inhibition at each ASO concentration was compared to
control using one-way ANOVA followed by Dunnett's multiple compar-
ison test (JMP Version 5.0.1, SAS Institute, Cary NC, USA). Signiﬁcant in-
hibition was deﬁned at p b 0.05.
2.9.3. Cell culture and expression of hERG in CHO-K1 cells
ISIS 116847, ISIS 141923, ISIS 345198, ISIS 353512, and ISIS 379804
were tested in CHO-K1 cells. Cells were maintained in 90% Minimum
Essential Medium supplemented with 9% fetal bovine serum, 1%
penicillin–streptomycin, and 50 μg/mL Hygromycin B. Reagents were
obtained from Invitrogen Corporation (Carlsbad CA, USA). The hERG
cDNA, in a pcDNA3.1/zeo(−) expression vector, was cotransfected
with a surface marker protein, green ﬂuorescence protein (GFP), to
allow assessment of the transfection efﬁciency and identiﬁcation of
cells for electrophysiological study. Plasmidswere transiently expressed
in cells using Lipofectamin2000 (Invitrogen Corporation, Carlsbad CA,
USA).
2.9.4. Electrophysiological recordings in CHO-K1 Cells
All testing was conducted in whole-cell patch-clamp experiments
performed in the voltage-clampmode.With the exception of the evalu-
ation of ISIS 345198, cells were superfused with a control external solu-
tion containing 143 mM NaCl; 5.4 mM KCl; 5.0 mM HEPES; 0.5 mM
MgCl2; 16.6 mM Glucose; and 1.8 mM CaCl2 (pH 7.4; titrated with
NaOH). While within the acceptance range, the salt content for the lot
of material used for evaluation of ISIS 345198 was considered to be ele-
vated and the superfusing solution was modiﬁed to 137 mM NaCl;
4.0 mM KCl; 10.0 mM HEPES; 1.0 mM MgCl2; 10.0 mM Glucose; and
1.8 mMCaCl2 (pH 7.4was titratedwithNaOH). For all the ASOs, themi-
cropipettes were ﬁlled with an intracellular solution containing
130 mM KCl; 1 mM MgCl2; 5 mM EGTA; 5 mM MgATP; and 5 mM
HEPES (pH 7.2; titrated with KOH). Reagents were obtained from
Sigma-Aldrich Co. (St. Louis MO, USA), with the exception of KOH
(Junsei Chemical Co. Ltd., Tokyo, Japan).
All experiments were conducted at 37 °C. Current signals were am-
pliﬁed and digitized by an Axopatch 200B ampliﬁer (Axon Instruments,
Inc., Union City CA, USA) and analyzed using the pCLMAP software
package (version 8.0, Molecular Devices, LLC, Sunnyvale CA, USA) and
SigmaPlot2000 (SPSS Inc., Chicago IL, USA). Cells were clamped at a
holding potential of−80 mV. After establishing thewhole-cell conﬁgu-
ration, stimulation protocols were applied successively and the induced
currents recorded. Cellswere depolarized for 2 s to 20 mV followed by a
3 second repolarization back to−40 mV. After the control stimuli were
applied, the extracellular solution was changed to a solution containing
ASO. Additional stimuli were then applied and the peaks of the inward
tail-currents analyzed.
For ISIS 116847 and ISIS 379804, concentrations were 15, 75, and
150 μM; ISIS 345198 concentrations were 15, 50, 75, and 150 μM; ISIS
141923 was tested at 150 μM, and ISIS 353512 concentrations were
Table 3
Summary of the hERG assay for various ASOs.
hERG assay ASO Concentration (μM)
10 15 25 50 75 100 108 150 300 324
HEK293 cellsa 487660 – – – – – – ✓ – – ✓
420476 – – ✓ ✓ – ✓ – ✓ – –
CHO-K1 cellsa 116847 – ✓ – – ✓ – – ✓ – –
379804 – ✓ – – ✓ – – ✓ – –
345198 – ✓ – ✓ ✓ – – ✓ – –
141923 – – – – – – – ✓ – –
a Cells were transfected with hERG cDNA.
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and after application of each ASO. Relative remaining currents were
calculated as initial current amplitude/current amplitude in the pres-
ence of ASO = relative remaining current. Concentration response rela-
tions were calculated by a non-linear least squares ﬁt [Hill equation;
f = xb/(cb + xb); b = Hill coefﬁcient, c = IC50] to the individual data
points. The positive control for each assay, E-4031, was tested at a con-
centration of 100 nM.
3. Results
For the in vivo studies, a summary of the study type, species used for
evaluation, the speciﬁc ASO, and the dose range evaluated is given in
Table 2. A similar summary of the concentration range for each ASO in
the hERG assay is provided in Table 3.
3.1. Effects of ASOs on neurobehavior
Subcutaneous administration of ISIS 487660 at up to 300 mg/kgwas
not associated with changes in neurobehavior or body temperature in
male or female mice. Similarly, male mice receiving up to 250 mg/kg
ISIS 420476 produced no meaningful changes in behavior, locomotor
activity, or body temperature. There were no primary neurobehavioral
effects noted in male or female rats administered a single dose of up
to 250 mg/kg ISIS 353512, or in rats administered repeat doses
(3 doses total) of ISIS 116847, ISIS 379804, ISIS 345198 or ISIS
141923 at up to 150 mg/kg/dose.
Transient changes in body temperature, and an increased incidence
of diarrhea, were noted in associationwith ASO administration. A statis-
tically signiﬁcant, but relativelyminimal (0.7 °C), decrease in body tem-
perature was found at 30 min post-dose for female rats, but not male
rats, with a single 250 mg/kg dose of ISIS 353512 (Table 4). Also
shown in Table 4, potential treatment-related observation of an in-
creased incidence of diarrhea was noted in males at 30 to 180 min
and in females at 30 and 90 min post-dose. With repeated administra-
tion of ISIS 116874, ISIS 378804, ISIS 345198, or ISIS 141923, mild
(b1 °C) and occasionally statistically signiﬁcant differences of increased
or decreased mean body temperature were noted post-dose on Day 8
(Table 5); however, statistically signiﬁcant differences in mean body
temperature were also found pre-dose for ISIS 116847, ISIS 345198,Table 2
Summary of the in vivo studies for CNS, respiratory, and cardiovascular systems with various A
Study type Species (strain) ASO Dose (mg/kg)
Cont. 12
CNS Mouse
(CD-1)
420476 ✓ –
487660 ✓ –
CNS
(single dose)
Rat
(SD)
353512 ✓ –
CNS
(repeat dose)
Rat
(SD)
116874 ✓ –
379804 ✓ –
345198 ✓ –
141923 ✓ –
Respiration Mouse
(CD-1)
420476 ✓ –
Respiration
(single dose)
Rat
(SD)
353512 ✓ –
Respiration
(repeat dose)
Rat
(SD)
116847 ✓ –
379804 ✓ –
345198 ✓ –
141923 ✓ –
Cardiovascular Rat
(SD)
116847 ✓ –
379804 ✓ –
345198 ✓ –
141923 ✓ –
Cardiovascular Monkey
(cynomolgus)
487660 ✓ ✓
420476 ✓ ✓
SD = Sprague–Dawley. All doses were administered by subcutaneous injection. For repeat doand ISIS 141923. Inmonkey, amild (b1 °C) and occasionally statistically
signiﬁcance decreased body temperature was noted for the 12 and
40 mg/kg ISIS 420476 groups proximate to 2 to 3 h post-dose (Table 6).
3.2. Effects of ASOs on respiration
No treatment-related changes in respiratory rate, tidal volume or
minute volume were found in mice administered up to 250 mg/kg ISIS
420746. Following a single dose of ISIS 353512 at up to 250 mg/kg in
the rat, no changes in respiration rate, tidal volume, or minute volume
were noted. Repeat dosing of ISIS 116847, ISIS 379804, ISIS 345198, or
ISIS 141923 at up to 150 mg/kg/dose was also found to be without
meaningful change in respiratory function in rat. Therewere no changes
in respiratory rate (collected via telemetry) or arterial blood gases (PO2,
PCO2, pH, and SO2%) associated with the administration of ISIS 487660
in monkeys.
3.3. Effects of ASOs on cardiovascular system
In the rat, a statistically signiﬁcant decrease in heart rate was noted
with 150 mg/kg ISIS 345198, ISIS 141923, and ISIS 116847 at 45 min
post-dose, and with 100 and 150 mg/kg ISIS 379804 and 150 mg/kg
ISIS 345198 at 90 min post-dose (Table 7). The relatively modest and
transient changes in heart rate were not associated with changes in
mean blood pressure. No differences in heart rate were noted at 180
or 360 min post-dose, and no changes in heart rate or blood pressure
were noted at 50 mg/kg for any of the four ASOs or time points evaluat-
ed. Of note, the 45 and 90 minute time frame is the same in whichSOs.
40 50 100 150 250 300
– ✓ ✓ – ✓ –
✓ – ✓ – – ✓
– ✓ ✓ – ✓ –
– ✓ ✓ ✓ – –
– ✓ ✓ ✓ – –
– – – ✓ – –
– – – ✓ – –
– ✓ ✓ – ✓ –
– ✓ ✓ – ✓ –
– ✓ ✓ ✓ – –
– ✓ ✓ ✓ – –
– – – ✓ – –
– – – ✓ – –
– ✓ ✓ ✓ – –
– ✓ ✓ ✓ – –
– – – ✓ – –
– – – ✓ – –
✓ – – – – –
✓ – – – – –
sing, rats were dosed on Days 1, 4 and 8.
Table 4
Body temperature and incidence of diarrhea in male and female rats administered a single intravenous dose of ISIS 353512.
Endpoint Sex Dose
(mg/kg)
Pre-dose 30 min 90 min 180 min 360 min 24 h
Body temperature (°C)a Male 0 38.1 ± 0.2 38.2 ± 0.2 38.2 ± 0.2 38.1 ± 0.2 38.0 ± 0.2 38.1 ± 0.1
50 38.2 ± 0.1 38.2 ± 0.2 38.2 ± 0.2 38.1 ± 0.2 38.0 ± 0.2 38.2 ± 0.1
100 38.2 ± 0.2 38.2 ± 0.2 38.2 ± 0.2 38.0 ± 0.1 38.0 ± 0.2 38.2 ± 0.2
250 38.3 ± 0.2 38.1 ± 0.2 38.1 ± 0.1 38.0 ± 0.1 38.1 ± 0.2 38.0 ± 0.3
Female 0 38.8 ± 0.2 39.0 ± 0.2 38.9 ± 0.2 38.8 ± 0.2 38.2 ± 0.1 38.8 ± 0.1
50 38.8 ± 0.2 38.7 ± 0.3 38.8 ± 0.2 38.7 ± 0.2 38.3 ± 0.2 38.8 ± 0.1
100 38.9 ± 0.3 38.5 ± 0.5 38.9 ± 0.3 38.6 ± 0.2 38.3 ± 0.2 38.7 ± 0.2
250 38.9 ± 0.3 38.3 ± 0.4* 38.7 ± 0.2 38.6 ± 0.2 38.4 ± 0.2 38.6 ± 0.4
Incidence of diarrhea Male 0 0/10 0/10 0/10 0/10 0/10 0/10
50 0/10 4/10 2/10 0/10 0/10 0/10
100 0/10 7/10 5/10 4/10 0/10 0/10
250 0/10 7/10 6/10 6/10 0/10 0/10
Female 0 0/10 0/10 0/10 0/10 1/10 0/10
50 0/10 3/10 1/10 0/10 0/10 0/10
100 0/10 4/10 1/10 0/10 0/10 0/10
250 0/10 7/10 5/10 0/10 0/10 0/10
aValues represent the mean ± S.D.; n = 10/group; statistically signiﬁcant difference from control group: *p b 0.05.
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considering that there is no clear evidence of a direct ASO-dependent ef-
fect on cardiac function, the biological signiﬁcance of these observations
for heart rate is in question.
Continuousmonitoring in telemeterizedmonkeys allowed for greater
dynamics in the evaluation of ASOs for cardiovascular effects. Blood col-
lected at 4 hpost-subcutaneous injection conﬁrmeddose dependent sys-
temic exposure of ISIS 487660with groupmean levels of 34.5 μg/mL and
84.5 μg/mL for the 12 and 40 mg/kg doses, respectively. No signiﬁcant
(statistical or biological) effect on systolic, diastolic, or mean arterial
blood pressure, or heart rate was observed. For clarity of presentation,
mean arterial pressure data and mean heart rate prior to dosing
(−60 min) and post-dose from 60 to 360 min are shown for the control
and 12 and 40 mg/kg groups in Fig. 1. As found in the ﬁrst 5 h post-dose,
there were no changes noted at the latter time points (out to 24 h post-
dose).
There were no treatment-related effects on PR, RR, QRS, and QT in-
tervals or changes in waveform rhythm or morphology for the electro-
cardiograms. There was a statistically signiﬁcant decrease in QRS
duration at baseline (−60 min) and the 240 minute time point for theTable 5
Effects of ISIS 116847, ISIS 379804, ISIS 345198 and ISIS 141923 on body temperature in rats p
Treatment Dose (mg/kg) Pre-dose 45 min
Temperature(°C) males
PBS 0 38.8 ± 0.1 38.2 ±
ISIS 116847 50 38.5 ± 0.2 38.3 ±
100 38.6 ± 0.3 38.2 ±
150 38.3 ± 0.1* 37.7 ±
ISIS 379804 50 38.4 ± 0.2 38.3 ±
100 38.5 ± 0.3 38.4 ±
150 38.4 ± 0.2* 38.3 ±
ISIS 345198 150 37.9 ± 0.4** 37.9 ±
ISIS 141923 150 38.1 ± 0.4* 38.2 ±
Temperature (°C) females
PBS 0 39.0 ± 0.5 39.1 ±
ISIS 116847 50 38.9 ± 0.2 38.9 ±
100 39.0 ± 0.3 38.7 ±
150 39.0 ± 0.1 38.4 ±
ISIS 379804 50 39.1 ± 0.2 39.1 ±
100 39.1 ± 0.3 38.8 ±
150 39.2 ± 0.2 39.0 ±
ISIS 345198 150 39.0 ± 0.5 39.1 ±
ISIS 141923 150 38.9 ± 0.2 38.9 ±
Rats were dosed on Days 1, 4 and 8 of the study. Each value represents the mean ± S.D.; n =
(PBS): *p b 0.05 and **p b 0.01.12 mg/kg group, as compared to control (Table 8). This decrease in
QRS duration was considered random day to day variability. Similarly,
there was a statistically signiﬁcant increase in QTcF noted for the
40 mg/kg dose at 60 min post-dose (353.6 ± 10.9) relative to the PBS
control at this time point (318.4 ± 13.1), however, this was within
the variation of the control group (ranged from 318.4 ± 13.1 to
357.4 ± 16.7) during the course of the study and thus was not consid-
ered to be a meaningful observation. No ISIS 487660-related effects
were found for the HR corrected QT intervals (QTcF and QTcI) at any
other time points.
There were no changes in mean systolic, diastolic, or arterial blood
pressure or heart rate; and no meaningful changes were noted for the
ECG parameters (mean RR interval, PR interval, QRS duration, QT inter-
val, and corrected QC (QTc) interval) following administration of ISIS
420476. Of note, statistically signiﬁcant differences between the treat-
ment and control days were noted for several of the endpoints, with
the majority of these occurring proximal to dose administration on
Day 4 (treatment) or after 1 h post-dose, a time point at which a sched-
uled blood samplewas collected. This response is evident in LSmean ar-
terial pressure (MAP) and LSmean heart rate values shown in Fig. 2. There-dose and following subcutaneous administration on Day 8.
90 min 180 min 360 min
0.1 37.9 ± 0.1 37.5 ± 0.3 37.5 ± 0.3
0.1 38.3 ± 0.1 37.3 ± 0.1 37.2 ± 0.1
0.4 38.2 ± 0.6 37.5 ± 0.2 37.4 ± 0.4
0.1* 37.8 ± 0.5 37.3 ± 0.0 37.2 ± 0.1
0.3 38.1 ± 0.3 37.4 ± 0.2 37.3 ± 0.1
0.2 38.3 ± 0.3* 37.0 ± 0.1** 37.2 ± 0.2
0.3 38.0 ± 0.1 37.6 ± 0.1 37.3 ± 0.1
0.3 38.0 ± 0.2 37.1 ± 0.4 37.1 ± 0.2*
0.4 38.1 ± 0.5 37.3 ± 0.4 37.1 ± 0.3
0.5 38.9 ± 0.6 38.0 ± 0.3 37.4 ± 0.1
0.3 38.7 ± 0.6 37.9 ± 0.2 37.3 ± 0.3
0.2 38.6 ± 0.2 38.5 ± 0.3 37.6 ± 0.4
0.2* 38.7 ± 0.2 37.3 ± 0.2 37.4 ± 0.1
0.1 38.8 ± 0.3 37.7 ± 0.1 37.5 ± 0.2
0.3 38.7 ± 0.2 37.6 ± 0.3* 37.6 ± 0.2
0.2 39.1 ± 0.1 37.8 ± 0.7* 37.5 ± 0.3
0.5 38.9 ± 0.6 38.0 ± 0.3 37.4 ± 0.1
0.3 38.7 ± 0.6 37.9 ± 0.2 37.3 ± 0.3
4/group; statistically signiﬁcant difference from control group (phosphate buffered saline
Table 6
Mean body temperature (°C) following subcutaneous dosing of ISIS 420476 in cynomolgus monkey.
Dose
(mg/kg)
0.5 h 1 h 1.5 h 2 h 2.5 h 3 h 3.5 h 4 h 4.5 h 5 h
0 38.90 ± 0.24 38.75 ± 0.12 38.68 ± 0.16 38.98 ± 0.11 38.98 ± 0.13 38.78 ± 0.14 38.55 ± 0.14 38.60 ± 0.13 38.45 ± 0.14 38.73 ± 0.13
12 38.80 ± 0.24 38.42 ± 0.12 38.80 ± 0.16 38.45 ± 0.11* 38.37 ± 0.13* 38.60 ± 0.14 38.60 ± 0.14 38.57 ± 0.13 38.62 ± 0.14 38.70 ± 0.13
0 38.77 ± 0.22 38.40 ± 0.14 38.40 ± 0.13 38.75 ± 0.10 38.62 ± 0.08 38.45 ± 0.10 38.47 ± 0.08 38.30 ± 0.11 38.30 ± 0.11 38.55 ± 0.12
40 38.53 ± 0.22 38.10 ± 0.14 38.38 ± 0.13 38.13 ± 0.10* 38.00 ± 0.08* 38.18 ± 0.10 38.25 ± 0.08 38.30 ± 0.11 38.38 ± 0.11 38.50 ± 0.12
Values represent the LSmean ± LSM s.e.; n = 4; statistically signiﬁcant difference from control group: *p b 0.05. A pre-dose value was not collected, comparison for ISIS 420476-treated
monkeys is made to the corresponding value for the control group at each time point.
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a transient increase associated with handling of the animals for dosing
of PBS or ISIS 420476 (0 min). Upon blood collection at 1 h post-dose,
MAP rapidly increased following ISIS 420476 administration, as com-
pared to control, and required 0.75 to 1 h to return to levels similar to
that on Day 1. Heart rate demonstrated a similar decreasing trend
after dosing until the sharp increase at approximately 1 h. Fluctuations
in heart rate were evident though 4 to 5 h post-dose, after which values
for the control and treatment days demonstrated more similar heart
rates. Due to the timing of these ﬁndings the changes were considered
to be not directly related to ISIS 420476, but rather to the design and
conduct of the study. Furthermore, while reaching statistical signiﬁ-
cance the values remainedwithin the overall range of values noted dur-
ing collection of the control data. As an example, LSmean values for the
QRS duration at selected time points is provided in Table 6. At 2 h post-
dose the QRS duration was elevated for the 12 and 40 mg/kg groups, as
compared to each group's matching control data; however, the results
were within the minimum and maximum values observed across all
time points for each group's matching control data.
3.4. Effects of ASOs on hERG current in HEK293 and CHO-K1 cells
Representative tracings from the hERG assay in HEK293 cells for ISIS
420476 at the 150 μM concentration and E-4031 at 0.5 μM are
displayed in Fig. 3. The concentration-response for ISIS 420476
(expressed as mean ± s.e.m.) demonstrated a hERG current reduction
of 5.2 ± 1.4%, 6.1 ± 1.3%, 8.9 ± 1.6%, and 8.6 ± 1.8% at 25, 50, 100
and 150 μM, respectively; the values for the 100 and 150 μMconcentra-
tions were statistically signiﬁcantly different from control (1.2 ± 0.7%).Table 7
Effects of ISIS 116847, ISIS 379804, ISIS 345198 and ISIS 141923 on mean blood pressure and h
Treatment Dose (mg/kg) 0 min 45 min
Mean blood pressure (mm Hg)
PBS 0 91.8 ± 7.91 95.5 ± 11.37
ISIS 116847 50 94.4 ± 10.96 94.5 ± 10.89
100 82.9 ± 3.67 87.5 ± 5.21
150 92.2 ± 7.28 91.7 ± 8.10
ISIS 379804 50 93.1 ± 9.29 89.4 ± 7.72
100 95.0 ± 5.16 98.6 ± 5.48
150 97.4 ± 2.20 97.9 ± 3.90
ISIS 345198 150 89.2 ± 11.76 88.9 ± 9.78
ISIS 141923 150 100.6 ± 6.57 98.6 ± 9.41
Heart rate (BPM)
PBS 0 362.7 ± 29.58 382.2 ± 18.61
ISIS 116847 50 376.3 ± 25.59 365.6 ± 14.89
100 366.1 ± 44.48 355.5 ± 21.94
150 363.0 ± 28.28 332.2 ± 16.80
ISIS 379804 50 349.4 ± 36.32 355.4 ± 26.36
100 338.0 ± 19.86 345.3 ± 31.66
150 342.5 ± 23.48 346.0 ± 40.35
ISIS 345198 150 348.1 ± 55.11 337.6 ± 29.24
ISIS 141923 150 358.3345198 354.6 ± 55.11
Values represent the mean ± S.D. n = 6; PBS, ISIS 116847 150 mg/kg, ISIS 379804 50 mg/kg
group: *p b0.05 and **p b 0.01.A clear reduction in hERG current was found for the positive control,
60 nM terfenadine, with values ranging from 77.9% to 81.4%. No appar-
ent reduction in the hERG current was found for ISIS 487660 in HEK293
cells with values of 0.2 ± 0.8% at 108 μM and 0.9 ± 0.4% at 324 μM, as
compared to 1.0 ± 0.6% for the negative control and approximately 84%
reduction for the positive control (60 nM terfenadine). An IC50 value
could not be calculated for ISIS 420476 due to the modest changes
across the concentration range, and datawas too limited for calculations
for ISIS 487660; however, the inhibitory effect of hERG current was es-
timated to be greater than 150 μM and 324 μM, respectively.
In CHO-K1 cells, reduction in the hERG-current (mean ± s.e.m.)
with ISIS 353512 was found to be 0.8 ± 0.6%, 0.2 ± 1.0%, 4.1 ± 1.6%
and 0.6 ± 1.4% at concentrations of 10, 50, 150, and 300 μM, respective-
ly, as compared to 3.5 ± 1.6% for the superfusing solution only, or an
88 ± 1.4% reduction with 100 nM E-4031. Values for ISIS 116847
(−2.0 ± 0.6%, −0.4 ± 1.9% and 2.1 ± 1.1%) or ISIS 379804
(−1.9 ± 1.0%,−0.7 ± 0.6% and 3.4 ± 0.7%) at 15, 75 or 150 μM, re-
spectively, and ISIS 141923 (2.9 ± 1.6%) at 150 μMwere not statistical-
ly or biologically signiﬁcant for reduction in hERG potassium current. As
described, the superfusing solution for ISIS 345198 contained a lower
concentration of NaCl and KCl, nevertheless, ISIS 345198was associated
with a statistically signiﬁcantly reduced hERG current at the higher
concentrations of 75 μM (22.5 ± 3.4%) and 150 μM (30.2 ± 0.8%), a
modest decrease (9.5 ± 2.4%) at 50 μM, and no apparent reduction
(1.9 ± 2.1%) at 15 μM. With the latter four ASOs, the hERG current for
the superfusing solution group was found to be 0.8 ± 0.6%, and for
E-4031 (100 nM) the reduction in hERG current was 94.1 ± 0.1%. For
each of the ASOs evaluated in CHO-K1 cells, the IC50 was predicted to
be N150 μM.eart rate in rats.
90 min 180 min 360 min
93.9 ± 10.52 90.9 ± 8.36 94.4 ± 7.35
94.1 ± 7.81 98.9 ± 9.40 94.6 ± 12.79
84.2 ± 6.07 87.8 ± 4.58 88.1 ± 5.86
92.4 ± 11.63 95.5 ± 9.45 93.0 ± 10.93
88.7 ± 10.10 92.3 ± 6.87 90.5 ± 5.48
98.3 ± 6.43 96.3 ± 6.35 95.1 ± 4.18
97.8 ± 3.97 99.4 ± 5.01 99.8 ± 4.68
88.3 ± 10.99 88.8 ± 11.31 90.0 ± 9.12
100.6 ± 7.12 99.6 ± 7.32 101.2 ± 6.21
374.4 ± 20.52 340.8 ± 19.79 351.7 ± 24.28
365.7 ± 24.44 376.1 ± 38.77 360.6 ± 20.10
357.7 ± 39.73 346.2 ± 37.35 350.1 ± 38.45
⁎⁎ 349.8 ± 41.02 338.4 ± 29.26 345.8 ± 27.05
346.9 ± 20.94 319.5 ± 35.58 320.3 ± 35.04
328.4 ± 21.32⁎⁎ 322.9 ± 20.28 334.7 ± 18.07
321.4 ± 16.21⁎⁎ 316.4 ± 31.70 325.0 ± 21.31
⁎ 333.6 ± 36.75⁎ 341.6 ± 26.57 326.4 ± 28.44
⁎ 357.6 ± 29.24 338.5 ± 36.75 342.2 ± 26.57
and ISIS 141923 150 mg/kg, n = 5 others. Statistically signiﬁcant difference from control
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Fig. 1. Left panel:Mean arterial pressure (MAP) in cynomolgusmonkey pre-dose (−60 min) and to 360 minpost-dose following subcutaneous administration of ISIS 487660. Right panel:
Heart rate in cynomolgus monkey during the same time interval. Values are the group mean ± s.e.m. (n = 4).
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The respiratory system was speciﬁcally evaluated for six ASOs, one
in mouse and ﬁve in the rat. Consistent with ICH S7A, respiratory rate
and a second measurement, tidal volume, were directly measured by
plethysmograph. With up to 250 mg/kg in mouse or rat, there were
no effects that were considered to be of toxicological concern or biolog-
ically meaningful. Furthermore, respiratory end points were included
for assessment of ISIS 487660 in telemeterized monkeys at up to
40 mg/kg, with no effect on respiratory rate or blood gases, including
hemoglobin oxygen saturation (SO2%), a core battery endpoint for the
respiratory system. These results are consistent with published reports
on the toxicology of similar ASOs, e.g., phosphorothioate (PS) backbone
DNA sequences and PS mixed DNA/2′MOE sequences (Henry et al.,
2002, 2012; Levin et al., 2001; Zanardi et al., 2012), in which no indica-
tions of adverse respiratory effects have been reported.
Neurobehavior was directly assessed through Functional Observa-
tion Battery (FOB) tests of two ASOs in mouse and ﬁve in rat. While
the speciﬁc endpoints varied among the studies, each study involved
multiple endpoints spanning observation of signs (e.g., locomotor activ-
ity) to physical manipulation (e.g., grip strength) for potential CNSTable 8
Effects of ISIS 487660 or ISIS 420476 on QRS duration (milliseconds) following subcutaneous d
ISIS 487660
Dose
(mg/kg)
−60 min 60 min 120 min 180 min
0 39.5 ± 1.3 39.0 ± 1.3 39.0 ± 1.8 38.9 ± 1.6
12 37.6 ± 1.8* 37.9 ± 1.8 38.5 ± 1.6 37.3 ± 2.3
40 38.7 ± 1.6 38.6 ± 1.9 39.1 ± 2.2 39.2 ± 2.1
Values represent the mean ± s.e.m.; n = 4; statistically signiﬁcant difference from control g
ISIS 420476
Dose
(mg/kg)
60 min 120 min 180 min 240 min
0 34.2 ± 0.9 33.2 ± 0.8 35.7 ± 0.6 36.9 ± 0
12 34.3 ± 0.9 35.8 ± 0.8* 35.8 ± 0.6 36.1 ± 0
0 34.6 ± 0.7 33.8 ± 0.4 34.8 ± 0.4 35.3 ± 0
40 33.4 ± 0.7 35.2 ± 0.4* 33.9 ± 0.4 34.2 ± 0
Values represent the LSmean ± LSM s.e.; n = 4; statistically signiﬁcant difference from contro
420476-treated monkeys is made to the corresponding value for the control group at each timeffects. No adverse effects were noted among the seven ASOs evaluated
for this core physiological system.
Body temperature is listed within the evaluation parameters for
assessment of the CNS, as per ICH S7A. As such, this endpoint was in-
cluded in the evaluation in the mouse (one ASO) and rat (ﬁve ASOs).
Body temperature was alsomeasured within the cardiovascular studies
in monkey (two ASOs). There were no apparent changes in body tem-
perature in mouse. In rat, body temperatures were increased or de-
creased with no clear pattern post-dose. ISIS 487660 had no apparent
impact on body temperature in monkey, whereas ISIS 420476 was
noted with decreased mean body temperature. Considering that the
magnitude of change was minimal, never exceeding a 1 °C difference
between treated and controls for rat or monkey, the change in body
temperature was considered to be not adverse.
The proximity to dosing and trend for higher dose levels suggest an
underlying reason for ﬂuctuation in body temperature. Similarly, tran-
sient observations of diarrhea for ISIS 353512 in rat was most promi-
nent at the highest dose. The absence of alteration in the multiple FOB
endpoints suggests that the variations in body temperature and diar-
rhea are not mediated by a direct action within the CNS. Furthermore,
these observations occurred with sequences to diverse targets, variedosing in cynomolgus monkey.
240 min 300 min 360 min 720 min 24 h
39.3 ± 1.7 39.0 ± 1.7 38.5 ± 1.3 39.2 ± 1.4 39.1 ± 1.6
37.4 ± 2.1* 37.6 ± 1.8 38.0 ± 1.9 39.5 ± 2.3 37.8 ± 2.0
39.0 ± 2.1 38.4 ± 2.0 38.4 ± 1.9 39.5 ± 2.2 38.0 ± 2.2
roup: *p b 0.05.
300 min 360 min 720 min 24 h
.5 35.9 ± 0.6 35.6 ± 0.8 37.6 ± 0.7 34.4 ± 1.3
.5 36.8 ± 0.6 36.4 ± 0.8 37.6 ± 0.7 36.1 ± 1.3
.6 34.8 ± 0.2 34.1 ± 0.7 36.1 ± 0.7 35.1 ± 0.7
.6 34.9 ± 0.3 34.9 ± 0.7 36.1 ± 0.7 35.1 ± 0.7
l group: *p b 0.05. For ISIS 420476 a pre-dose value was not collected, comparison for ISIS
e point.
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Fig. 2.Mean arterial pressure (MAP) and heart rate in cynomolgusmonkey following subcutaneous administration of 12 mg/kg (upper left and lower left panels, respectively) or 40 mg/kg
(upper right and lower right panels, respectively) ISIS 420476 on Day 4, as compared to matching control data from Day 1. Values are expressed as the Least SquareMean; n = 4/group.
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141923), indicating no target-related (on- or off-target) association. A
more likely reason for changes in body temperature is secondary to a
non-speciﬁc inﬂammatory response. Immune stimulation in rodents
has been consistently reported to occur with ASOs (Farman &10000
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Fig. 3. Representative trace for the effects 150 μM ISIS 420476 and 0.5 μM E-4031 on hERG pot
sium currents obtained in a single cell as evoked by the voltage protocol shown in the lower pan
indicate the control period, and ASO and E-4031 exposure periods.Kornbrust, 2003; Henry, Templin, Gillett, Rojko, & Levin, 1999;
Monteith & Levin, 1999), but secondary actions, such as changes in
body temperature, may demonstrate temporal variation and were de-
tected in these studies as a result of the frequent repeated measure-
ments post-dose.2000
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assium current in HEK293 cells. Left panel: upper panel [Current (pA)] shows hERG potas-
el [Voltage (mV)]. Right panel: peak current amplitude during application, horizontal bars
2 0.021 mg/mL × (1 mmol/7000 mg) × (1000 mL/1 L) × (1000 μmol/mmol) = 3 μM
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certain biological signiﬁcance as therewas no change in blood pressure.
Only ISIS 345198 at 150 mg/kg had two consecutive data points of sta-
tistical signiﬁcance. ISIS 345198 has not been evaluated for impacts on
cardiovascular function in non-human primates andmaywarrant addi-
tional follow-up studies to determine if there is a biological signiﬁcance
to these observations.
Continuousmonitoring of cardiovascular parameters in telemeterized
monkeys administered ISIS 420476 or ISIS 487660 demonstrated no ef-
fects on the mechanical function, e.g., vascular pressure and rate of con-
tractions, in the heart. Examination of the ECG tracings and calculation
of key intervals (e.g., QRS) further supports an absence of any ASO-
dependent actions on electrical conductance in the heart. The occasional
value of statistical signiﬁcance found among the various time points and
parameters within or across studies did not demonstrate a trend or con-
sistency. Moreover, when examined with consideration of the variability
in each measured parameter found in the control group across time
points or across the control and treated groups at pre-dose, the values
found to be statistically signiﬁcant were within the normal expected
range further conﬁrming no biological signiﬁcance and no direct actions
on cardiovascular function. Cardiac-based adverse effects reported with
ASOs inmonkeyhavebeendirectly associatedwith activation of the com-
plement system,most prominently the alternative pathway (Henry et al.,
1997, 1999, 2002).
Consistent with the absence of any change in quantitative ECGmea-
surements in treated monkeys, there was no biologically meaningful
change in hERG function noted among the seven ASOs. This was not un-
expected as the most common means of adverse effects on hERG is di-
rect actions within the channel pore (Stanﬁeld, Sutcliffe, & Mitcheson,
2006; Thomas, Karle, & Kiehn, 2006), and as such the relatively large
molecular size and hydrophobicity of an ASO suggests a low potential
for inhibition.
No inhibition of hERG channel currentwas noted forﬁve of theASOs.
Although the results for ISIS 345198 indicate a modest impact of 20% to
30% inhibition, this occurred at concentrations of 75 μM or higher.
The change in hERG channel current with ISIS 420476 was less than
10% with concentrations of N100 μM. While the observations for the
latter two ASOs were of interest, the magnitude of the response
must be taken into consideration. Katchman, Koerner, Tosaka,
Woosley, and Ebert (2006) proposed four categories for hERG inhibition:
high-potency blockers (IC50 b 0.1 μM), moderate-potency blockers
(0.1 μM b IC50 b 1.0 μM), low-potency blockers (IC50 N 1.0 μM), and
ineffective blockers (IC50 N 300 μM). The positive controls, E-4031 and
terfenadine, used in the assays fell within the high-potency category.
Each of the ASOs, including ISIS 345198, had an IC50 of N150 μM or
N300 μM, placing them in the low-potency to ineffective category.
The hERG assay is one for which properties of ASOs and the test sys-
tem should be considered. Temperature, salt content, and osmolarity
have been implicated as confounding factors (Kirsch et al., 2004;
Yabuuchi, Beckmann, Wettwer, Hegele-Hartung, & Heubach, 2007).
Temperature was well controlled in these studies, and would not be
expected to be impacted by an ASO. As relatively large molecules
(MW of 5000 to 8000 Da) that are highly charged, ASOs can impart
oncotic pressure. Furthermore, they are known to contain sodium and
other monovalent cationic salts as counter ions to the 20 negatively
charged PS backbone residues. These secondary factors would demon-
strate an increased potential for inﬂuencing the results with increased
concentration, i.e., an apparent dose–response, and thus may play an
additive role in the observations of modest changes in hERG channel
current at high concentrations.
Furthermore, a cell-based system does not reﬂect the inﬂuence that
protein binding may have on ASO-cell interactions. ASOs have been
shown to be highly protein bound in plasma (Geary et al., 2001;
Watanabe, Geary, & Levin, 2006), with free ASO b10% of the total plas-
ma concentration. Yu et al. (2007) reported a Cmax of approximately
21 μg/mL following a 200 mg intravenous dose of an ASO in humans.Based on this information and MW of 7000 Da for a standard ASO,
this roughly equates to a 3 μM2 total concentration, and 0.3 μM free
concentration. Thus, the highest concentrations evaluated in the hERG
assay exceeded a reasonable total plasma concentration by up to
100× and a free plasma concentration by 1000×. This is well above
the 30× margin that has been proposed by Redfern et al. (2003) for
compounds thatmay interferewith hERGpotassiumchannels. Subcuta-
neous dosing results in much lower plasma concentrations of an ASO,
and thus lower potential for interactions with cell surface proteins.
The ASOs can also be examined for general characteristics. In regards
to the hERG assay, all seven of the ASOswere evaluatedwith at least one
concentration in the range of 100 μM to 150 μM. This concentration
greatly exceeds plasma levels of ASO in studies in monkey as noted for
ISIS 487660 with levels of ~5 μM (~35 μg/mL) or ~12 μM (~85 μg/mL),
the ~5 μM, and that reported for a 4 mg/kg intravenous infusion of an
ASO in monkey or ~3 μM concentration described above for a represen-
tative human dose (Yu et al., 2007).
Of interest, mAb have been identiﬁed as a class of drugs for which
hERG testing is likely to be of limited or no direct beneﬁt (Vargas
et al., 2008). This was based on low potential to interact with the extra-
cellular or intracellular domains of the hERG channel, target-speciﬁc
binding properties, and large molecular size (~140,000 Da). ASOs
share the high speciﬁcity for binding and structural attributes (highmo-
lecular size and nucleic acid composition) that appear to limit the po-
tential for direct hERG inhibition, and at least warrant consideration of
a similar approach to that summarized by Vargas et al. (2008). As the
published knowledge base for PS DNA/MOE ASOs increases this point
should be reviewed for a consensus among the various parties involved
in Research and Development of nucleic acid-based pharmaceuticals.
The Oligonucleotide Safety Working Group (OSWG) has been
established that includes a consortium of individuals working in drug
development companies and university settings, and this is a likely
source of a consensus review on safety pharmacology testing for ASOs.
In vivo studies are, of course, essential for evaluation of potential car-
diovascular effects, and for effects on other key systems. ASOs were
evaluated in the mouse or rat with at least one dose level in the range
of 100 to 150 mg/kg, a range that represents a ≥30-fold multiple
above clinical doses (McGowan et al., 2012; Ricotta & Frishman, 2012;
Stein et al., 2012; Yu et al., 2007). No effects were noted for respiration,
and no primary effects were noted for CNS. The 40 mg/kg dose in mon-
key is 4- to 10-fold above common clinical doses, and inclusion of the
results for respiration and the cardiovascular systems further indicates
no unwanted actions on these core systems. The absence of direct ad-
verse effects on CNS, and the respiratory and cardiovascular systems is
consistent with published data (Farman & Kornbrust, 2003; Henry
et al., 1997, 1999, 2002, 2012; Levin et al., 2001; Monteith & Levin,
1999; Zanardi et al., 2012) covering the toxicology for a number of
ASOs within the class of PS DNA/MOE ASOs.
While the objectives of safety pharmacology studies encompass key
information required for a thorough analysis, much of the data needed
to meet regulatory guidance can be obtained within other studies,
e.g., the inclusion of cardiac function and cardiac parameters (e.g. QT in-
terval), in GLP toxicology studies. This point is addressed for safety
pharmacology in ICH S9, in which it states that safety pharmacology
could be included in general toxicology studies when the conduct of
stand-alone studies is not called for. In consideration of PS DNA/MOE
ASOs, dedicated studies focused on speciﬁc organ systems do not appear
to add signiﬁcant data for the interpretation of potential adverse effects.
Therefore, the need for dedicated studies for future ASOs in the same
class is questionable, rathermore encompassing data for cardiac and re-
spiratory function and neurobehavior can be collected in repeated dose
and longer-term toxicology studies.
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